YZY Bio is a biotechnology company that develops anti-tumor bispecific antibodies.
YZY Bio is a biotechnology company that develops anti-tumor bispecific antibodies based on breakthrough discoveries in molecular biology, enabling patients with major diseases to obtain more efficient treatment solutions.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 4, 2022 | Series C | ¥200M | — | — | — | Detail |
Sep 13, 2021 | Series B | ¥250M | 4 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
TD Capital | — | Series B |
Sanhua Hongdao Investment | — | Series B |
Wuhan Institute of Biotechnology | — | Series B |
BGI Co-Win | — | Series B |